Genmab AS (OCSE:GMAB) Interest Expense : kr-98 Mil (TTM As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Genmab AS Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Genmab AS's interest expense for the three months ended in Dec. 2024 was kr -54 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was kr-98 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Genmab AS's Operating Income for the three months ended in Dec. 2024 was kr 2,191 Mil. Genmab AS's Interest Expense for the three months ended in Dec. 2024 was kr -54 Mil. Genmab AS's Interest Coverage for the quarter that ended in Dec. 2024 was 40.57. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Genmab AS Interest Expense Historical Data

The historical data trend for Genmab AS's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Interest Expense Chart

Genmab AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-10.00

-13.00

-39.00

-70.00

-120.00

Genmab AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-21.00	-7.00	-19.00	-18.00	-54.00

Genmab AS Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-98 Mil.

Genmab AS (OCSE:GMAB) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Genmab AS's Interest Expense for the three months ended in Dec. 2024 was kr-54 Mil. Its Operating Income for the three months ended in Dec. 2024 was kr2,191 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was kr937 Mil.

Genmab AS's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2024 )	/	Interest Expense (Q: Dec. 2024 )
	=	-1	*	2191	/	-54
	=	40.57

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Genmab AS has enough cash to cover all of its debt. Its financial situation is stable.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OCSE:GMAB) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:USA GMABc:UK 0MGB:UK GE91:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.